… Annual General Meeting of Shareholders and Provides Leadership Updates Annual General Meeting of Shareholders to … Platenburg to assume Chief Scientific Officer role, with leadership oversight of Axiomer ® RNA-editing platform …
… to Daniel de Boer, Founder and CEO. In this newly created leadership position, Ms. Heggie will be responsible for … and CEO. “Theresa brings a wealth of commercial and leadership skills to ProQR, having built commercial …
ProQR Therapeutics is a clinical-stage biotech company listed on NASDAQ with offices in Leiden, the Netherlands and Cambridge, Massachusetts, US. ProQR is focused on the development of game-changing RNA therapies for severe rare and common diseases.
ProQR Therapeutics is a biotechnology company listed on NASDAQ with offices in Leiden, the Netherlands and Cambridge, Massachusetts, USA. ProQR is focused on the development of life changing RNA therapies to meet the unmet need of individuals and families with common and rare diseases.
… M.D., Chief Development Strategy Officer will assume leadership of clinical development at the Company. LEIDEN, … Strategy Officer, David M. Rodman M.D, will assume leadership over clinical development. Additionally, the …
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023Management Team appointments and plann
LEIDEN, the Netherlands, March 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it appointed David M. Rodman, MD as Chief Development Strategy Officer. Dr.
